Jessica Fye
Stock Analyst at JP Morgan
(4.51)
# 273
Out of 5,162 analysts
216
Total ratings
63.97%
Success rate
14.53%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiates: Overweight | $30 | $18.99 | +57.98% | 1 | Feb 3, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $24 → $26 | $20.57 | +26.40% | 6 | Nov 4, 2025 | |
| STOK Stoke Therapeutics | Maintains: Neutral | $15 → $25 | $33.19 | -24.68% | 5 | Nov 3, 2025 | |
| NVCR NovoCure | Maintains: Neutral | $25 → $23 | $12.06 | +90.71% | 5 | Oct 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $204 → $199 | $178.55 | +11.45% | 5 | Oct 27, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $63 → $65 | $63.66 | +2.10% | 15 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Underweight | $26 → $25 | $52.56 | -52.44% | 14 | Oct 23, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $121 → $120 | $91.19 | +31.59% | 14 | Oct 23, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $475 → $473 | $313.41 | +50.92% | 9 | Oct 13, 2025 | |
| LEGN Legend Biotech | Maintains: Overweight | $78 → $76 | $18.75 | +305.33% | 4 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $89 | $92.54 | -3.83% | 9 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $119 | $58.51 | +103.38% | 5 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $260 → $264 | $225.98 | +16.82% | 16 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $517 → $530 | $469.34 | +12.92% | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $345 → $385 | $284.05 | +35.54% | 4 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $49 → $80 | $71.19 | +12.38% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $52 | $37.49 | +38.70% | 6 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $77 | $90.66 | -15.07% | 4 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $34 → $35 | $27.76 | +26.08% | 7 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $111 → $135 | $139.50 | -3.23% | 9 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $350 → $330 | $536.12 | -38.45% | 17 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.22 | +58.15% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $30.86 | +62.02% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $28.00 | +7.14% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $73.25 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.07 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.44 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.34 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.74 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.69 | +314.20% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.24 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.70 | - | 1 | Feb 8, 2018 |
Aktis Oncology
Feb 3, 2026
Initiates: Overweight
Price Target: $30
Current: $18.99
Upside: +57.98%
Denali Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $20.57
Upside: +26.40%
Stoke Therapeutics
Nov 3, 2025
Maintains: Neutral
Price Target: $15 → $25
Current: $33.19
Upside: -24.68%
NovoCure
Oct 27, 2025
Maintains: Neutral
Price Target: $25 → $23
Current: $12.06
Upside: +90.71%
Jazz Pharmaceuticals
Oct 27, 2025
Maintains: Overweight
Price Target: $204 → $199
Current: $178.55
Upside: +11.45%
Halozyme Therapeutics
Oct 27, 2025
Maintains: Neutral
Price Target: $63 → $65
Current: $63.66
Upside: +2.10%
Moderna
Oct 23, 2025
Maintains: Underweight
Price Target: $26 → $25
Current: $52.56
Upside: -52.44%
BioNTech SE
Oct 23, 2025
Maintains: Neutral
Price Target: $121 → $120
Current: $91.19
Upside: +31.59%
Alnylam Pharmaceuticals
Oct 13, 2025
Maintains: Overweight
Price Target: $475 → $473
Current: $313.41
Upside: +50.92%
Legend Biotech
Oct 9, 2025
Maintains: Overweight
Price Target: $78 → $76
Current: $18.75
Upside: +305.33%
Oct 9, 2025
Maintains: Neutral
Price Target: $73 → $89
Current: $92.54
Upside: -3.83%
Oct 9, 2025
Maintains: Overweight
Price Target: $116 → $119
Current: $58.51
Upside: +103.38%
Oct 9, 2025
Maintains: Overweight
Price Target: $260 → $264
Current: $225.98
Upside: +16.82%
Oct 8, 2025
Maintains: Overweight
Price Target: $517 → $530
Current: $469.34
Upside: +12.92%
Oct 8, 2025
Maintains: Overweight
Price Target: $345 → $385
Current: $284.05
Upside: +35.54%
Oct 8, 2025
Upgrades: Overweight
Price Target: $49 → $80
Current: $71.19
Upside: +12.38%
Sep 24, 2025
Maintains: Overweight
Price Target: $53 → $52
Current: $37.49
Upside: +38.70%
Sep 12, 2025
Maintains: Overweight
Price Target: $53 → $77
Current: $90.66
Upside: -15.07%
Sep 9, 2025
Maintains: Neutral
Price Target: $34 → $35
Current: $27.76
Upside: +26.08%
Aug 20, 2025
Maintains: Overweight
Price Target: $111 → $135
Current: $139.50
Upside: -3.23%
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $536.12
Upside: -38.45%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.22
Upside: +58.15%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $30.86
Upside: +62.02%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $28.00
Upside: +7.14%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $73.25
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.07
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.44
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.34
Upside: -
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $0.74
Upside: -
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.69
Upside: +314.20%
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $10.24
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $12.70
Upside: -